Skip to main content
SpringerLink
Log in

Prostatakarzinom: palliative Therapie

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Die Urologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 73 Accesses

Zusammenfassung

Ist eine kurative Therapie aufgrund des lokal fortgeschrittenen oder metastasierten Primärbefundes nicht mehr möglich oder wünscht der Patient bei lokal begrenzter Erkrankung keine kurative Behandlungsoption, kommen palliative Therapiekonzepte zum Tragen. Aufgrund des häufig langsamen Erkrankungsverlaufs kann diese palliative Phase beim Prostatakarzinom viele Jahre umfassen. Bei relevanten Begleiterkrankungen begrenzen häufig konkurrierende Todesursachen die Lebenserwartung. Die erweiterte Hormontherapie stellt den Standard der palliativen Therapie dar. Im kastrationsresistenten Stadium haben sich neben der Chemotherapie eine Vielzahl neuer Substanzen etabliert, für die eine gute Symptomkontrolle sowie eine Verbesserung des medianen Gesamtüberlebens nachgewiesen werden konnten. Neben neuen Ansätzen zur Hormonmanipulation und der PARP-Inhibitor-Therapie bei BRCA1/2-Mutation erweitern auch nuklearmedizinische Ansätze das therapeutische Spektrum. Ergänzende Supportivmaßnahmen und eine angepasste Schmerztherapie haben während der gesamten Erkrankungsdauer einen sehr hohen Stellenwert. Vor allem zur Behandlung von symptomatischen Metastasen kommt hierbei der Strahlentherapie eine wichtige Rolle zu.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M (2017) Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging 44:1448–1454. https://doi.org/10.1007/s00259-017-3716-2

    Article  CAS  PubMed  Google Scholar 

  • Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29:1335–1341

    Article  PubMed  PubMed Central  Google Scholar 

  • Armstrong AJ et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974–2986. http://www.ncbi.nlm.nih.gov/pubmed/31329516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 57:1006–1013. https://doi.org/10.2967/jnumed.115.168443

    Article  CAS  PubMed  Google Scholar 

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) PREVAIL Investigators Enzalutamid in metastatic prostate cancer before chemotherapy. New Engl J Med 371:424–433

    Article  PubMed  Google Scholar 

  • Beer TM et al (2017) Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 71(2):151–154. http://www.ncbi.nlm.nih.gov/pubmed/27477525. Zugegriffen am 10.12.2021

  • Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  CAS  PubMed  Google Scholar 

  • Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–2264

    Article  CAS  PubMed  Google Scholar 

  • Bono JS de, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Google Scholar 

  • Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L (1998) Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83:1995–2002

    Article  CAS  PubMed  Google Scholar 

  • Chi KN et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24. http://www.ncbi.nlm.nih.gov/pubmed/31150574. Zugegriffen am 10.12.2021

  • Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436

    Article  PubMed  Google Scholar 

  • Clarke et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992–2003. https://pubmed.ncbi.nlm.nih.gov/31560068/. Zugegriffen am 10.12.2021

  • Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28:788–798

    Article  CAS  PubMed  Google Scholar 

  • Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131. https://doi.org/10.1056/NEJMoa1903835. https://pubmed.ncbi.nlm.nih.gov/31157964/. Zugegriffen am 10.12.2021

  • Deek MP, Tran PT (2020) Oligometastatic and oligoprogression disease and local therapies in prostate cancer. Cancer J 26:137–143. https://doi.org/10.1097/PPO.0000000000000432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eisenberger M, Hardy-Bessard AC, Kim CS et al (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35(28):3198–3206. https://doi.org/10.1200/JCO.2016.72.1076. https://pubmed.ncbi.nlm.nih.gov/28809610/. Zugegriffen am 10.12.2021

  • Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, Stief C, Bartenstein P, Gratzke C, Lehner S, Rominger A (2017) Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 8:3581–3590. https://doi.org/10.18632/oncotarget.12240

    Article  PubMed  Google Scholar 

  • Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA-301 Investigators (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K et al (2019a) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235–1246. http://www.ncbi.nlm.nih.gov/pubmed/30763142. Zugegriffen am 10.12.2021

  • Fizazi K et al (2019b) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686–700. http://www.ncbi.nlm.nih.gov/pubmed/30987939. Zugegriffen am 10.12.2021

  • Fizazi K et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11):1040–1049. http://www.ncbi.nlm.nih.gov/pubmed/32905676. Zugegriffen am 10.12.2021

  • Friedlander JI, Duty BD, Okeke Z, Smith AD (2012) Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies. J Endourol 26:102–109

    Article  PubMed  Google Scholar 

  • Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T (2020) Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol 196:589–597. https://doi.org/10.1007/s00066-020-01598-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Gravis G et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158. http://www.ncbi.nlm.nih.gov/pubmed/23306100

    Article  CAS  PubMed  Google Scholar 

  • Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M (2016) Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol 196:382–391. https://doi.org/10.1016/j.juro.2016.02.2969

    Article  CAS  PubMed  Google Scholar 

  • Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J, SPCG-5 Study Group (2008) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 42:220–229

    Article  CAS  PubMed  Google Scholar 

  • Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S (2018) [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825–833. https://doi.org/10.1016/S1470-2045(18)30198-0

    Article  CAS  PubMed  Google Scholar 

  • Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–935

    CAS  PubMed  Google Scholar 

  • Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314–1325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hussain M et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383(24):2345–2357. http://www.ncbi.nlm.nih.gov/pubmed/32955174. Zugegriffen am 10.12.2021

  • James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177. http://www.ncbi.nlm.nih.gov/pubmed/26719232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • James ND et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351. http://www.ncbi.nlm.nih.gov/pubmed/28578639. Zugegriffen am 10.12.2021

  • Kantoff PW, Mohler JL (2013) New developments in the management of prostate cancer. J Natl Compr Cancer Netw 11:653–657

    Article  CAS  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  CAS  PubMed  Google Scholar 

  • Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H, PROSTY study Group (2013) 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14:117–124

    Article  CAS  PubMed  Google Scholar 

  • Kraeber-Bodéré F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27:1487–1493

    Article  PubMed  Google Scholar 

  • Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A (2018) Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med 59:795–802. https://doi.org/10.2967/jnumed.117.203539

    Article  CAS  PubMed  Google Scholar 

  • Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL (2005) Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174:2186–2190

    Article  PubMed  Google Scholar 

  • Magnan S et al (2015) Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol 1(9):1261–1269. http://www.ncbi.nlm.nih.gov/pubmed/26378418. Zugegriffen am 10.12.2021

  • Nariculam J, Murphy DG, Jenner C, Sellars N, Gwyther S, Gordon SG, Swinn MJ (2009) Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol 82:571–576

    Article  CAS  PubMed  Google Scholar 

  • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  • Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O’Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

    Article  PubMed  PubMed Central  Google Scholar 

  • Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648

    Article  PubMed  Google Scholar 

  • Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M (2016) Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 41:522–528. https://doi.org/10.1097/RLU.0000000000001240

    Article  PubMed  Google Scholar 

  • Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90. https://doi.org/10.2967/jnumed.116.183194

    Article  CAS  PubMed  Google Scholar 

  • Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR (2020) Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging 47:713–720. https://doi.org/10.1007/s00259-019-04584-1

    Article  CAS  PubMed  Google Scholar 

  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE (2015) COU-AA-302 Investigators Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160

    Article  CAS  PubMed  Google Scholar 

  • Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637–643

    Article  CAS  PubMed  Google Scholar 

  • Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A (2019) 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138. https://doi.org/10.1007/s00259-018-4167-0

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed  Google Scholar 

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    Article  CAS  PubMed  Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164

    Article  CAS  PubMed  Google Scholar 

  • Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B, HERO Study Investigators (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187–2196. https://doi.org/10.1056/NEJMoa2004325

    Article  CAS  PubMed  Google Scholar 

  • Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408–419. https://doi.org/10.1016/S1470-2045(18)30860-X

    Article  CAS  PubMed  Google Scholar 

  • Smith MR et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418. http://www.ncbi.nlm.nih.gov/pubmed/29420164. Zugegriffen am 10.12.2021

  • Smith MR et al (2020) Apalutamide and overall survival in prostate cancer. Eur Urol 79(1):150–158. http://www.ncbi.nlm.nih.gov/pubmed/32907777

    Article  PubMed  Google Scholar 

  • Sternberg CN et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197–2206. http://www.ncbi.nlm.nih.gov/pubmed/32469184. Zugegriffen am 10.12.2021

  • Sweeney CJ et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. http://www.ncbi.nlm.nih.gov/pubmed/26244877. Zugegriffen am 10.12.2021

  • Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM (2013) Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistent prostate cancer. Clin Cancer Res 19:5182–5891

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  • Thomas DJ, Balaji VJ, Coptcoat MJ, Abercrombie GF (1992) Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial? J R Soc Med 85:318–319

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G (1998) A randomised comparison of ‚Casodex‘ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447–456

    Article  CAS  PubMed  Google Scholar 

  • Wit, R. de, et al., Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer, N Engl J Med, 2019. 381(26): S. 2506–2518. http://www.ncbi.nlm.nih.gov/pubmed/31566937. Zugegriffen am 10.12.2021

  • Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C (2017) 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 44:81–91. https://doi.org/10.1007/s00259-016-3481-7

    Article  CAS  PubMed  Google Scholar 

  • Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blümle A, Schmucker C, Mayer B, Kunath F (2021) Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev 8:CD012548. https://doi.org/10.1002/14651858.CD012548.pub2

Leitlinien

  • Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F (2008) European Association of Nuclear Medicine. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35:1934–1940

    Article  PubMed  Google Scholar 

  • Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen (S1). Deutsche Gesellschaft für Nuklearmedizin. http://www.nuklearmedizin.de/leistungen/leitlinien/html/radionuk_ther.php?navId=53. Zugegriffen am 24.08.2021 angemeldet unter AWMF-Registernummer: 031–029

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.0. AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen am 24.08.2021

  • Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS (2021) Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol 205:22–29. https://doi.org/10.1097/JU.0000000000001376

    Article  PubMed  Google Scholar 

  • Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Gillessen S, Grummet J, Henry AM, van der Kwast TH, Lam TB, Mason MD, O’Hanlon S, Oprea-Lager DE, Ploussard G, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T (2021) EAU guidelines on prostate cancer. European Association of Urology

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Marburg, Philipps-Universität Marburg, Marburg, Deutschland

    Johannes Huber

  2. Klinik für Urologie, Zeisigwaldkliniken Bethanien Chemnitz, Dresden, Deutschland

    Michael Fröhner

  3. Klinik und Poliklinik für Urologie, Universitätsklinkikum Carl Gustav Carus, Dresden, Deutschland

    Manfred Wirth

  4. Klinik und Poliklinik für Nuklearmedizin, Universitätsklinkikum Carl Gustav Carus, Dresden, Deutschland

    Jörg Kotzerke & Claudia Brogsitter

  5. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Deutschland

    Tobias Hölscher

Authors
  1. Johannes Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Fröhner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jörg Kotzerke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Brogsitter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tobias Hölscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Huber .

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Universitätsmedizin Mannheim, Mannheim, Baden-Württemberg, Deutschland

    Maurice Stephan Michel

  2. Klinik für Urologie, Universitätsklinikum Mainz, Mainz, Deutschland

    Joachim W. Thüroff

  3. Abt. für Urologie, Universitätsklinikum Salzburg, Salzburg, Salzburg, Österreich

    Günther Janetschek

  4. Klinik und Poliklinik für Urologie, Univer Tech Univ Dresden, Dresden, Sachsen, Deutschland

    Manfred P. Wirth

Section Editor information

  1. Klinik für Urologie, Zeisigwaldkliniken Bethanien Chemnitz, Dresden, Deutschland

    Manfred Wirth

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Huber, J., Fröhner, M., Wirth, M., Kotzerke, J., Brogsitter, C., Hölscher, T. (2022). Prostatakarzinom: palliative Therapie. In: Michel, M.S., Thüroff, J.W., Janetschek, G., Wirth, M.P. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_144-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-41168-7_144-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-41168-7

  • Online ISBN: 978-3-642-41168-7

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Prostatakarzinom: palliative Therapie
    Published:
    26 November 2022

    DOI: https://doi.org/10.1007/978-3-642-41168-7_144-2

  2. Original

    Prostatakarzinom: palliative Therapie
    Published:
    29 April 2015

    DOI: https://doi.org/10.1007/978-3-642-41168-7_144-1

Search

Navigation